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). GVHD, GVL, and the associated cytokines may help drive sustained donor engraftment, particularly in patients who have previously rejected an allogeneic graft. Where a strong GVL is needed for an anti-tumor effect and GVHD is desired to promote sustained engraftment, strategies to allow the desired immune response to continue while tempering undesired toxicity to the patient are often attempted. These strategies may include topical application of drugs, under the assumption that there will be only local, not systemic, absorption. We report the first case of significant systemic absorption of a topical medication in cutaneous acute GVHD, and advise that care be taken when administering topical medications to patients with cutaneous GVHD.
A white male, 2 years 8 months old, underwent matched unrelated donor bone marrow transplantation for X-linked autoimmunity allergic dysregulation syndrome (XLAAD) (reviewed in Ferguson et al 2 ). He had developed insulindependent diabetes mellitus, atopic dermatitis, and multiple food allergies within the first year of life. XLADD is a lifethreatening, inherited disorder that also afflicted his older sibling and two maternal first cousins (details of the cases and their transplant course are reported separately). His brother and maternal cousin previously had difficulties with an ablative bone marrow transplant and needed donor lymphocyte infusion (DLI) and GVHD to achieve full donor engraftment. Therefore, the patient underwent matched-unrelated allogeneic BMT with a nonmyeloblative regimen of antithymocyte globulin (ATG), high-dose steroids, plasmapheresis, and post transplant DLI to boost engraftment, but he rejected the graft with demonstrable cytotoxic host-anti donor T lymphocytes. The patient underwent a second matched-unrelated donor BMT following a preparative regimen of cyclophosphamide and total-body irradiation, augmented with ATG and steroids followed by infusion of marrow from a second unrelated donor. Cyclosporine with short course methotrexate was given for GVHD prophylaxis.
His early posttransplant course was complicated by severe pneumonitis and early grade III histologic cutaneous GVHD treated with sirolimus, and he was restarted on cyclosporine beginning on day þ 48 and þ 60, respectively. Bone marrow biopsy and peripheral blood from day þ 62 showed him to be 99 and 100% donor, respectively. A bone marrow aspirate on day þ 92 showed him to be 89% donor, so immune suppression was discontinued on day þ 98. Experience with the patient's cousin and sibling had demonstrated that a state of mixed chimerism did not eliminate the symptoms of XLAAD and over time resulted in loss of donor cells. In addition, auto-reactive T cells of patients with XLAAD and T-cells derived from the animal model of the Scurfy mouse are less sensitive to cyclosporine than normal T cells. 3 The patient then developed skin GVHD that progressed from moderate truncal erythema to grade IV histologic GVHD with severe whole body erythema and desquamation. To encourage full donor engraftment and due to his previous history of graft rejection, systemic immunosuppression was avoided. His rash was initially treated with topical steroids. When he progressed to total-body erythema, topical pimecrolimus (Elidel cream) was added with his caregiver instructed to it apply as thinly as possible to his rash that now covered 75-100% of his body surface area. The patient had a dramatic response to the topical pimecrolimus with marked improvement in his rash. However, his serum tacrolimus level was found to be 54 ng/ml (therapeutic trough range in organ transplant recipients, 5-20 ng/ml) the morning following the third application of topical pimecrolimus. He had an altered mental status and mild elevation in serum creatinine both of which improved when the topical therapy was abruptly discontinued and his skin gently cleaned. His serum tacrolimus level fell over the next 8 days to a level of 2.3 mg/ml and monitoring of levels was discontinued. Table 1 summarizes GVHD treatment given in relation to use of pimecrolimus. On day þ 159 his peripheral blood was 100% donor. He again developed cutaneous GVHD, and sirolimus and cyclosporine were restarted.
Chimerism studies on PHA-stimulated lymphocytes at 6 months showed entirely donor engraftment. At 8 months status post BMT, the patient developed hemolytic uremic syndrome, recurrent pulmonary infiltrates, and had a rapid decline. The patient died 9 months post transplant. A endotracheal tube culture obtained on the day prior to his death grew adenovirus.
Cutaneous GVHD is usually the first, and most common, clinical manifestation of acute GVHD. The erythematous rash may spread over the entire body, and is often described as feeling similar to sunburn. In cutaneous GVHD there can be massive blood flow to the skin, so much so, that patients with hyperacute GVHD 4 have been reported to experience heart failure due to high output failure. 5 This high rate of blood flow to the skin can cause significantly increased systemic absorption of topical medications.
The patient presented here had XLAAD, a genetic disorder that is fatal without transplant. As a result of the risk of rejection especially after the second marrow graft in a patient with XLAAD, systemic immunosuppression was avoided despite the dramatic flair of skin GVHD 3 months post transplant.
Previous reports of systemic absorption, without toxic effects, of topical tacrolimus have been shown in patients with a breakdown in their epidermal barrier. In patients with primary dermatologic diseases, levels as high as 37.2 ng/ml have been reported. [6] [7] [8] [9] [10] The patients achieving elevated levels all had relatively rare dermatologic diseases, with a breakdown of the epidermal barrier, leading to an increase in percutaneous absorption of topical tacrolimus. 11, 12 In vitro studies show percutaneous absorption by healthy skin of 0.03, 0.1, and 0.3% topical tacrolimus ointments was 3.1, 4.9, and 6.8 ng/cm 2 /h, respectively, while damaged skin absorbed an average of 40 ng/cm 2 /h. 13 At the time the patient received topical pimecrolimus he was intensely erythrodermic and hot to the touch from the high rate of blood flow to his skin. He also had a damaged epidermal barrier from the GVHD. In addition, his age enhanced the risk for percutaneous toxicity due to the increased ratio of surface area to weight seen in the pediatric population. 12 These factors may have allowed significant systemic absorption of tacrolimus, leading to the level of 54 ng/ml seen.
We report this case of toxic systemic absorption of tacrolimus to alert physicians that patients receiving topical medications may have significant systemic absorption and potential toxicity. Patients with extensive skin breakdown, extensive erythroderma, and pediatric patients may be particularly prone to this problem. Grade IV skin Topical steroid and topical pimecrolimus 54 ng/ml after three applications +159
Grade IV skin Sirolimus and cyclosporine NA 100% in peripheral blood a NA ¼ not applicable.
